Eli Lilly (LLY), an Indianapolis-based company that is recognized for its recently approved Alzheimer’s drug Kisunla, weight loss drug Zepbound and diabetes medication Mounjaro, has announced plans to spend $1.8 billion to expand its pharmaceutical manufacturing facilities in Ireland to meet growing global demand.
Of the $1.8 billion, $1 billion will be used to expand its existing facility in Limerick dedicated to manufacturing its Alzheimer’s treatment, which was approved in July and slows the progression of the disease in the early stages. The remaining $800 million will be used to expand a facility in Kinsale which manufactures its diabetes and weight loss drugs, demand for which has exceeded supply over the last year.
These investments are in addition to the $20 billion the company has invested since 2020 to expand its presence in the U.S. and Europe. Stock in the company has risen 54 percent over the last year.
